Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

Saad Usmani, MD, FACP, Sarah Waheed, MD, Jackie Szymonifka, Susan Panozzo, Nathan M Petty, Doug Steward, Bijay Nair, MD, Yazan Alsayed, MD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 3995.

https://doi.org/10.1182/blood.V118.21.3995.3995

Published: 2011

Journal Articles

Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide

Christoph Heuck, MD, Jackie Szymonifka, Qing Zhang, PhD, Saad Usmani, MD, FACP, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 988.

https://doi.org/10.1182/blood.V118.21.988.988

Published: 2011

Journal Articles

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Saad Usmani, MD, FACP, Jackie Szymonifka, Rachael Sexton, Susan Panozzo, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, John Crowley, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 2947.

https://doi.org/10.1182/blood.V118.21.2947.2947

Published: 2011

Journal Articles

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Saad Usmani, MD, FACP, Alan Mitchell, Bijay Nair, MD, Sarah Waheed, MD, Frits van Rhee, MD, PhD, Yazan Alsayed, MD, Nathan M Petty, Doug Steward, Susan Panozzo, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3081.

https://doi.org/10.1182/blood.V118.21.3081.3081

Published: 2011

Journal Articles

Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

Saad Usmani, MD, FACP, Alan Mitchell, Rachael Sexton, Susan Panozzo, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 3082.

https://doi.org/10.1182/blood.V118.21.3082.3082

Published: 2011

Journal Articles

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

Jeffrey Sawyer, Erming Tian, PhD, John D. Shaughnessy, Jr., PhD, Janet Lukacs, Regina Lichti Binz, Edward Thomas, Gael Sammartino, Charles Swanson, Christoph Heuck, MD, Yazan Alsayed, MD, Elias J. Anaissie, MD, Bijay Nair, MD, Sarah Waheed, MD, Saad Usmani, MD, FACP, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2011) 118 (21): 298.

https://doi.org/10.1182/blood.V118.21.298.298

Published: 2011

Journal Articles

Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

Saad Usmani, MD, FACP, Rachael Sexton, Antje Hoering, PhD, Christoph Heuck, MD, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan M Petty, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 823.

https://doi.org/10.1182/blood.V118.21.823.823

Published: 2011

Journal Articles

Gene Expression Profiling (GEP) Analysis of Plasma Cells (PC) Obtained From MRI-Defined Focal Lesions (FL) Under CT-Guided Fine-Needle Aspiration Provides Better Risk Stratification in Patients with Multiple Myeloma

Qing Zhang, PhD, Pingping Qu, PhD, Emily Hansen, MS, Christoph Heuck, MD, Saad Usmani, MD, FACP, Bijay Nair, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Antje Hoering, PhD, John Crowley, PhD, John D Shaughnessy, Jr., PhD, Bart Barlogie, MD, PhD

Blood (2011) 118 (21): 2896.

https://doi.org/10.1182/blood.V118.21.2896.2896

Published: 2011

Journal Articles

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4 , as novel high-risk feature in myeloma treated with Total Therapy 3

John D. Shaughnessy, Jr, Pingping Qu, Saad Usmani, Christoph J. Heuck, Qing Zhang, Yiming Zhou, Erming Tian, Ichiro Hanamura, Frits van Rhee, Elias Anaissie, Joshua Epstein, Bijay Nair, Owen Stephens, Ryan Williams, Sarah Waheed, Yazan Alsayed, John Crowley, Bart Barlogie

Blood (2011) 118 (13): 3512–3524.

https://doi.org/10.1182/blood-2010-12-328252

Published: 2011

Includes: Supplemental data

Journal Articles

Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)

Yazan Alsayed, MD, Sarah Waheed, MD, Jackie Szymonifka, Bijay Nair, MD, MPH, Saad Usmani, MD, Frits van Rhee, MD, PhD, Elias J. Anaissie, MD, Monica Grazziutti, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1969.

https://doi.org/10.1182/blood.V116.21.1969.1969

Published: 2010

Journal Articles

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Antje Hoering, PhD, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, Monica Grazziutti, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 368.

https://doi.org/10.1182/blood.V116.21.368.368

Published: 2010

Journal Articles

Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants.

Bijay Nair, MD, MPH, Elias J. Anaissie, MD, Sarah Waheed, MD, Yazan Alsayed, MD, Rachael Sexton, Nathan Petty, Frits van Rhee, MD, PhD, Antje Hoering, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 1352.

https://doi.org/10.1182/blood.V116.21.1352.1352

Published: 2010

Journal Articles

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Sarah Waheed, MD, Bijay Nair, MD, MPH, Yazan Alsayed, MD, Monica Grazziutti, Elias J. Anaissie, MD, Frits van Rhee, MD, PhD, Nathan Petty, Doug Steward, Jackie Szymonifka, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 4800.

https://doi.org/10.1182/blood.V116.21.4800.4800

Published: 2010

Journal Articles

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD, Jackie Szymonifka, Elias J. Anaissie, MD, Bijay Nair, MD, MPH, Sarah Waheed, MD, Yazan Alsayed, MD, Nathan Petty, John Shaughnessy, Jr, PhD, Antje Hoering, PhD, John Crowley, PhD

Blood (2010) 116 (21): 1356.

https://doi.org/10.1182/blood.V116.21.1356.1356

Published: 2010

Journal Articles

Improved Outcome with Total Therapy 3 (TT3) In Comparison with Total Therapy 2 (TT2) Can Be Traced to GEP70-Defined High-Risk Disease with Trisomy of 1q21 and Modest but Not Marked Hyper-Activation of the Proteasome Gene PSMD4

John Shaughnessy, Jr., PhD, Pingping Qu, Erming Tian, Bijay Nair, MD, MPH, Sarah Waheed, MD, Yazan Alsayed, MD, Frits van Rhee, MD, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2010) 116 (21): 303.

https://doi.org/10.1182/blood.V116.21.303.303

Published: 2010

Journal Articles

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

Frits van Rhee, Jackie Szymonifka, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, John D. Shaughnessy, Jr, Antje Hoering, John Crowley, Bart Barlogie

Blood (2010) 116 (8): 1220–1227.

https://doi.org/10.1182/blood-2010-01-264333

Published: 2010

Journal Articles

Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

Bijay Nair, Frits van Rhee, John D. Shaughnessy, Jr, Elias Anaissie, Jackie Szymonifka, Antje Hoering, Yazan Alsayed, Sarah Waheed, John Crowley, Bart Barlogie

Blood (2010) 115 (21): 4168–4173.

https://doi.org/10.1182/blood-2009-11-255620

Published: 2010

Journal Articles

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Yiming Zhou, Lijuan Chen, Bart Barlogie, MD, PhD, Owen Stephens, PhD, Xiaosong Wu, PhD, David Williams, PhD, Marie-astrid Cartron, PhD, Frits van Rhee, MD, PhD, Bijay Nair, MD, Sarah Waheed, MD, Mauricio Pineda-Roman, MD, PhD, Yazan Alsayed, MD, PhD, Elias Anaissie, MD, PhD, John D Shaughnessy, Jr.

Blood (2009) 114 (22): 1804.

https://doi.org/10.1182/blood.V114.22.1804.1804

Published: 2009

Journal Articles

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

Bart Barlogie, MD, PhD, John D Shaughnessy, Jr., Elias Anaissie, MD, PhD, Frits van Rhee, MD, PhD, Yazan Alsayed, MD, PhD, Sarah Waheed, MD, Bijay Nair, MD, Monica Grazziutti, PhD, Vanessa Bolejack, PhD, John Crowley, PhD

Blood (2009) 114 (22): 744.

https://doi.org/10.1182/blood.V114.22.744.744

Published: 2009

Journal Articles

SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).

Sarah Waheed, MD, Yazan Alsayed, MD, PhD, Bijay Nair, MD, Jackie Szymonifka, John D Shaughnessy, Jr., Frits van Rhee, MD, PhD, Elias Anaissie, MD, PhD, Bart Barlogie, MD, PhD

Blood (2009) 114 (22): 3421.

https://doi.org/10.1182/blood.V114.22.3421.3421

Published: 2009

NARROW

Pomalidomide (Pom) in Relapsed and Refractory Multiple Myeloma (RRMM) - theUARK Compassionate Use Protocol,

Low Expression of Nuclear Glucocorticoid Receptor Gene NR3C1 in Newly Diagnosed Myeloma Correlates with Inferior Prognosis and Is Rescued by Thalidomide

Phase II Study of Carfilzomib (CFZ) Combined with Other Anti-Myeloma Agents in Relapsed-Refractory Multiple Myeloma (RRMM) - Updates on the UARK Compassionate Use Protocol

Total Therapy 6: Initial Results of Dose-Dense Strategy for Previously Treated Multiple Myeloma

Implications of Serial Magnetic Resonance Imaging and Positron Emission Tomography Scanning for Survival of Untreated Myeloma Patients Treated with Total Therapy 3

Jumping Translocations 1q12 Contribute to Copy Number (CN) Alterations in Multiple Myeloma (MM): Unexpected Focal Amplifications of Receptor Chromosomes (RC)

Second Malignancies in Total Therapy 3 Trials for Newly Diagnosed Multiple Myeloma: Influence of Lenalidomide Versus Thalidomide in Maintenance Phases

Gene Expression Profiling (GEP) Analysis of Plasma Cells (PC) Obtained From MRI-Defined Focal Lesions (FL) Under CT-Guided Fine-Needle Aspiration Provides Better Risk Stratification in Patients with Multiple Myeloma

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4 , as novel high-risk feature in myeloma treated with Total Therapy 3

Pacmed Salvage Therapy for Advanced High-Risk Multiple Myeloma (AHRMM)

Comparing Toxicities and Survival Outcomes with Total Therapy 4 (TT4) for 70-Gene (R70)-Defined Low-Risk Multiple Myeloma (MM) to Results Obtained with Total Therapy 3 Protocols TT3A and TT3B

Autotransplants for Multiple Myeloma (MM) – An Update of the Arkansas Experience Since 1989 In Almost 4000 Patients with Special Emphasis on Third and Further Transplants.

Super (S)-Beam for Advanced and Refractory Multiple Myeloma (ARMM)

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Contributions to Survival Outcomes of Dosing of Thalidomide (T), Dexamethasone (D) and Interferon (I) Maintenance Components.

Improved Outcome with Total Therapy 3 (TT3) In Comparison with Total Therapy 2 (TT2) Can Be Traced to GEP70-Defined High-Risk Disease with Trisomy of 1q21 and Modest but Not Marked Hyper-Activation of the Proteasome Gene PSMD4

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

High-Risk Multiple Myeloma Is Characterized by Uniform Over-Expression of Mirnas and Increased Copy Number and Expression of Argonaute 2 , A Master Regulator of Mirna Maturation and B-Cell Development.

Modeling for Cure with Total Therapy (TT) Trials for Newly Diagnosed Multiple Myeloma (MM): Let the Math Speak.

SUPER- BEAM (SB): Incorporation of Bortezomib, Thalidomide, Dexamethasone, Cisplatin and Rapamycin Into the BEAM Regimen for Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only